Today's Rundown Featured Story | | | Thursday, April 16, 2020 Insurers are under the gun to issue premium rates to state regulators in the next couple of months, but the unknown cost impact of COVID-19 poses a massive challenge, according to a new analysis. |
|
|---|
|
Top Stories Thursday, April 16, 2020 Two more vaccine makers are joining the hunt. Dynavax and Sinovac are teaming up on a vaccine for COVID-19, combining the former’s vaccine adjuvant with the latter’s chemically inactivated coronavirus vaccine candidate. Wednesday, April 15, 2020 Hackers are increasingly targeting small hospitals and health centers with ransomware attacks. This trend is particularly concerning since 80% of small practices do not have an in-house security official. Here are best practices to follow to protect your organization. Thursday, April 16, 2020 The COVID-19 pandemic is having a significant impact on Americans' mental health, a new report from Express Scripts shows. Thursday, April 16, 2020 Doses of hydoxychloroquine donated to the U.S. by Bayer are coming under fire after they may not have passed full FDA inspection for quality. Sources told Reuters about 3 million doses of the drug, named Resochin, have been donated so far. Thursday, April 16, 2020 FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Thursday, April 16, 2020 A report out by financial consultancy Moody’s has found that COVID-19 will hit the CRO industry but hopes the impact will be limited. Thursday, April 16, 2020 The FDA has accepted Regeneron’s filing for approval of the Ebola drug REGN-EB3 for priority review. REGN-EB3, which comes from the same platform as Regeneron’s COVID-19 antibodies, arrives at the FDA after outperforming ZMapp in a clinical trial. Thursday, April 16, 2020 With the coronavirus pandemic pausing FTC reviews and complicating supply chains, Mylan is flying a holding pattern on its megamerger with Pfizer's Upjohn unit and scrambling to deal with worldwide drug demand at the same time. Looking for a steady hand in trying times, Mylan found just the man for the job—again. |
|
